PCI High Potent Manufacturing
LB Bohle – 10.06.2025
Temax_Krautz

Current Edition

Current Edition

Subsection - CDMO

Examining how innovative technologies, integrated manufacturing approaches and AI are shaping manufacturing.

Continue reading

Subsection - Injectables

Exploring advances in injectable drug delivery and sterile manufacturing, designed to improve patient-centric delivery.

Continue reading

Subsection - Neurodegenerative Diseases

Exploring emerging approaches to neurodegenerative disease research and treatment.

Continue reading

Subsection - Nasal & Pulmonary

Highlighting how advances in nasal and pulmonary drug delivery, formulation, devices and analytics are enabling more complex therapies.

Continue reading

Advertisement

CPHI 2027
DDL 2026

Advertisement

Nipro August 26

Advertisement

Merxin March 2026

Advertisement

Aurisco 300×250

Advertisement

Lifecore Biomedical

Sanofi and Regeneron’s I-O med Libtayo, on a roll, puts up basal cell carcinoma win

Call it Libtayo’s month. After last week posting key data that could help it enter the lucrative non-small cell lung cancer market, the Sanofi and Regeneron immuno-oncology drug has rung up a win in advanced basal cell carcinoma.

In a phase 2 study of those who had already been treated with one prior therapy, the drug provoked a response in 29% of patients, the partners said Tuesday. And of those responders, about 85% saw the drug’s benefits last for at least a year.

The market is a wide-open one; there are no approved treatments for those whose disease progresses on—or those who are intolerant to—hedgehog pathway inhibitors, a class that includes Erivedge from Roche’s Genentech. About 20,000 U.S. patients per year develop advanced basal cell carcinoma, Sanofi and Regeneron said.

The companies are plotting regulatory submissions later this year, and if they can score an eventual FDA approval, it’ll reinforce Libtayo’s presence in the skin cancer field, where it already bears a green light—its first and only—in cutaneous squamous cell carcinoma.

But while the drug may be running that niche, it’s hardly alone in the wider skin cancer field. Its nemeses, checkpoint giants Keytruda from Merck and Opdivo from Bristol-Myers Squibb, have transformed the melanoma space since they debuted there several years back, and from there have gone on to rack up go-aheads in a wide array of cancers.

One of those cancers? NSCLC, where Libtayo is hoping to make its debut after last week showing it could top chemo at extending the lives of newly diagnosed patients. But once there, it would have to face Merck’s formidable Keytruda-chemo combo, which has dominated the market on the back of data showing it can slash patients’ risk of death by 51%.

Advertisement

MedPharm 16/07

Advertisement

Biopharma group march 2026

Advertisement

Silgan March 2026

Advertisement

Terumo 06/26

Advertisement

Scott Pharma – 25.03.2025

Advertisement

Bespak

Advertisement

Solstice

Advertisement

Bachem skyscraper
Tjoapack
Aptar – 08/01/2026